These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20217906)

  • 61. DNA 'caps' offer target for heart drugs.
    Harv Heart Lett; 2010 Jan; 20(5):7. PubMed ID: 20217906
    [No Abstract]   [Full Text] [Related]  

  • 62. Telomere biology and cardiovascular disease.
    Fuster JJ; Andrés V
    Circ Res; 2006 Nov; 99(11):1167-80. PubMed ID: 17122447
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Telomere biology in cardiovascular disease: the TERC-/- mouse as a model for heart failure and ageing.
    Wong LS; Oeseburg H; de Boer RA; van Gilst WH; van Veldhuisen DJ; van der Harst P
    Cardiovasc Res; 2009 Feb; 81(2):244-52. PubMed ID: 19047341
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Telomeres and cardiovascular disease: does size matter?
    Serrano AL; Andrés V
    Circ Res; 2004 Mar; 94(5):575-84. PubMed ID: 15031270
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Short telomere length a marker of premature vascular aging].
    Nilsson PM; Fyhrquist F
    Lakartidningen; 2007 Sep 26-Oct 2; 104(39):2801-5. PubMed ID: 17958006
    [No Abstract]   [Full Text] [Related]  

  • 66. Endothelial dysfunction and cardiovascular disease.
    Sherman DL; Loscalzo J
    Cardiologia; 1997 Feb; 42(2):177-87. PubMed ID: 9090161
    [No Abstract]   [Full Text] [Related]  

  • 67. [Cardiovascular pharmacology (VI). The current validity of old drugs: digoxin].
    Martín Luengo C; Arribas Jiménez A; Santos Rodríguez I; Castaño Bazo L; Sánchez López JL
    Rev Esp Cardiol; 1994 Nov; 47(11):754-67. PubMed ID: 7800906
    [No Abstract]   [Full Text] [Related]  

  • 68. Prognostic value of heart rate in cardiovascular disease.
    Sukonthasarn A
    J Med Assoc Thai; 2007 Nov; 90(11):2538-40. PubMed ID: 18181347
    [No Abstract]   [Full Text] [Related]  

  • 69. Oxidative stress and cardiovascular injury: Part II: animal and human studies.
    Griendling KK; FitzGerald GA
    Circulation; 2003 Oct; 108(17):2034-40. PubMed ID: 14581381
    [No Abstract]   [Full Text] [Related]  

  • 70. [Endothelin. II. The role of endothelin in the pathogenesis of disease].
    Siminiak T; Wysocki H
    Przegl Lek; 1994; 51(12):527-30. PubMed ID: 7746891
    [No Abstract]   [Full Text] [Related]  

  • 71. Nicotinamide adenine dinucleotide phosphate oxidase: a promiscuous therapeutic target for cardiovascular drugs?
    Muzaffar S; Shukla N; Jeremy JY
    Trends Cardiovasc Med; 2005 Nov; 15(8):278-82. PubMed ID: 16297764
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Can endothelium be treated with drugs?].
    Fyhrquist F
    Duodecim; 1993; 109(20):1841-7. PubMed ID: 7737007
    [No Abstract]   [Full Text] [Related]  

  • 73. [Chronobiologic aspects of therapy for cardiovascular diseases].
    Stepień M; Foks-Fratczak A
    Postepy Hig Med Dosw; 1999; 53(3):483-96. PubMed ID: 10424135
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pathophysiology of cardiovascular disease and renal failure.
    Dikow R; Zeier M; Ritz E
    Cardiol Clin; 2005 Aug; 23(3):311-7. PubMed ID: 16084280
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Endothelium--a new target for a therapeutic action of angiotensin-converting enzyme inhibitors].
    Karpov IuA
    Ter Arkh; 2004; 76(6):94-6. PubMed ID: 15332589
    [No Abstract]   [Full Text] [Related]  

  • 76. Therapeutical perspectives for apoptosis modulation in cardiovascular disease.
    Ginghină C; Crăciunescu I; Iorga V
    Rom J Intern Med; 2006; 44(3):213-22. PubMed ID: 18386601
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Thyroid hormones and the cardiovascular system: pathophysiology and interventions.
    Cini G; Carpi A; Mechanick J; Cini L; Camici M; Galetta F; Giardino R; Russo MA; Iervasi G
    Biomed Pharmacother; 2009 Dec; 63(10):742-53. PubMed ID: 19917524
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Angiotensin II AT2 subtype receptors: an emerging target for cardiovascular therapy.
    Volpe M; De Paolis P
    Ital Heart J; 2000 Feb; 1(2):96-103. PubMed ID: 10730608
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Platelet-active drugs in the secondary prevention of cardiovascular events: an overview.
    Weiss HJ
    Circulation; 1980 Dec; 62(6 Pt 2):V41-3. PubMed ID: 7002351
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Therapeutic implications of the gender-specific aspects of cardiovascular disease.
    Regitz-Zagrosek V
    Nat Rev Drug Discov; 2006 May; 5(5):425-38. PubMed ID: 16672926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.